ADMA Biologics Inc (ADMA) is a Healthcare · Biotechnology company listed on NASDAQ. Price $8.90 (-0.56%), Market cap $1.97B, P/E ratio 14.12, 52-week low–high $8.29 ~ $21.87.
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also de
Financial statements, price targets, institutional (13F) holdings and related news for ADMA Biologics Inc are updated in real time on BlackAll Trade.
ADMA Biologics Inc trades at $8.90 (-0.56%). Real-time quotes and charts are available on BlackAll Trade.
ADMA Biologics Inc has a market cap of about $1.97B. Its P/E ratio is 14.12.
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United